Delving into the Latest Updates on AS 900672-Enriched with Synapse

Overview

Basic Info

Drug Type

Hormone

Synonyms

FSH analogue, Follicle-stimulating hormone analogue, Glycosylated recombinant FSH

+ [3]

Target

FSHR

Mechanism

FSHR agonists(Follicle-stimulating hormone receptor agonists), Ovarian follicle stimulants

Therapeutic Areas

Urogenital Diseases

Active Indication-

Inactive Indication

Infertility

Originator Organization

Merck Serono SA

Active Organization-

Inactive Organization

Merck KGaA

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 2, interventional, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in oligo-anovulatory women undergoing ovulation induction (OI). This study will compare 4 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f ®) prefilled pen with regards to ovulation rate.

Start Date01 Dec 2007

Sponsor / Collaborator

Merck KGaA

NCT00505752

/ CompletedPhase 2

A Phase II, Multicenter, Randomized, Assessor-blinded, Active-comparator, Dose-finding Study to Evaluate AS900672 Enriched Versus Follitropin Alfa (Gonal-f®) in Stimulating Multiple Follicular Development in Infertile Women Undergoing Assisted Reproductive Technology (ART)

This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection [IVF/ICSI]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female [RFF] Pen) in regards to the number of fertilized oocytes.

Start Date01 Jan 2007

Sponsor / Collaborator

Merck KGaA

100 Clinical Results associated with AS 900672-Enriched

Login to view more data

100 Translational Medicine associated with AS 900672-Enriched

Login to view more data

100 Patents (Medical) associated with AS 900672-Enriched

Login to view more data

69

Literatures (Medical) associated with AS 900672-Enriched

01 Dec 2024·Journal of Assisted Reproduction and Genetics

Effect of follicle-stimulating hormone dose on the risk of being classified as suboptimal responders according to the POSEIDON criteria

Article

Author: Yarali, Hakan ; Vuong, Lan N ; Hochberg, Alyssa ; Esteves, Sandro C ; Dahan, Michael H

PURPOSEThe purpose of this study is to investigate the impact of daily follicle-stimulating-hormone (FSH) dose on the likelihood of suboptimal response to ovarian stimulation (OS) for in vitro fertilization (IVF) according to POSEIDON's criteria.METHODSA tri-center retrospective cohort study (2015-2017) including women with normal anti-Müllerian hormone (AMH ≥ 1.2 ng/mL) and antral follicle count (AFC ≥ 5) values per POSEIDON's criteria, undergoing their first IVF/ICSI cycle using conventional OS (FSH ≥ 150 IU/day). Suboptimal response was the retrieval of 4-9 oocytes. In previous research, we detected an AMH ≤ 2.97 ng/mL and AFC ≤ 12 as the optimal cut-offs predicting suboptimal response. Therefore, we examined the effect of daily FSH dose (≤ 300 IU versus > 300 IU) on suboptimal response risk for each AMH and AFC value within these thresholds (AMH between 1.20 and 2.97 ng/mL, by 0.01 ng/mL increments; and an AFC between 5 and 12, by unit increments). Analysis involved contingency tables and multivariable logistic regression.RESULTSIncluded were 4005 patients with AMH and AFC values in the specific range, among whom 2131 (53.2%) were suboptimal responders. Among 177 AMH groups analyzed, apart from three distributed irregularly, daily FSH doses > 300 IU versus lower doses (≤ 300 IU) did not decrease suboptimal response risk; similarly, higher doses did not decrease risk at the eight AFC values examined (p > 0.05 for all). Using multivariable logistic regression, FSH doses were not associated with suboptimal response risk. Conversely, female age, AMH, AFC, and gonadotropin type were associated with suboptimal response.CONCLUSIONSIn women with AMH values between 1.20 and 2.97 ng/mL and/or AFC between 5 and 12, FSH dose increase did not decrease suboptimal response risk. Individualizing the gonadotropin regimen and considering LH activity supplementation to FSH may mitigate risks.

01 Jun 2024·Reproduction in Domestic Animals

Association between metabolic parameters and embryo production in superovulated dairy cattle

Article

Author: Tirpan, Mehmet Borga ; Erişek, Abdülkadir ; Coşkun, Muhammed İkbal ; Satilmiş, Muharrem ; Ünay, Engin ; Yilmaz, Mehmet Ali ; Okuroğlu, Alaeddin ; Ünal, İlker ; Kaya, Ufuk ; Say, Erkan ; Sevgi, Ramazan

AbstractThis study aims to investigate the relationship between metabolic parameters and the number of embryos produced in superovulated cows with high genetic characteristics in milk yield. Eighteen Holstein donors were treated with classic superovulation protocols, AI and flushing. During superovulation, decreasing doses of FSH (follicle‐stimulating hormone) were administered at 12‐h intervals for 4 days. Plasma insulin‐like growth factor (IGF1), glucose (GLU), beta‐hydroxybutyric acid (BHB), non‐esterified fatty acid (NEFA), blood urea nitrogen (BUN) and total protein (TP) levels were determined by using an autoanalyzer. The mixed model analysis of variance was used for statistical analysis. As a result, plasma IGF1, BHB and BUN had significant interactions with both groups and days (p < .05). Additionally, plasma TP–days interactions were significant (p < .05). Furthermore, there was a negative correlation between the number of embryos and plasma BHB levels (p < .05). In conclusion, under appropriate environmental conditions, metabolic profile control of donors can contribute to the embryo production process and to the studies on the metabolic infrastructure.

01 Mar 2024·Arteriosclerosis, Thrombosis, and Vascular Biology

FSH Is Responsible for Androgen Deprivation Therapy–Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion

Article

Author: Du, Yiqing ; Wang, Qiang ; Geng, Xueyu ; Liang, Zhenhui ; Yao, Weijuan ; Xu, Tao ; Zhou, Jing ; Han, Jingli

BACKGROUND:Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer. But ADTs with orchiectomy and gonadotropin-releasing hormone (GnRH) agonist are associated with increased risk of cardiovascular diseases, which appears less significant with GnRH antagonist. The difference of follicle-stimulating hormone (FSH) in ADT modalities is hypothesized to be responsible for ADT-associated cardiovascular diseases.METHODS: We administered orchiectomy, GnRH agonist, or GnRH antagonist in male ApoE−/− mice fed with Western diet and manipulated FSH levels by testosterone and FSH supplementation or FSH antibody to investigate the role of FSH elevation on atherosclerosis. By combining lipidomics, in vitro study, and intraluminal FSHR (FSH receptor) inhibition, we delineated the effects of FSH on endothelium and monocytes and the underlying mechanisms. RESULTS:Orchiectomy and GnRH agonist, but not GnRH antagonist, induced long- or short-term FSH elevation and significantly accelerated atherogenesis. In orchiectomized and testosterone-supplemented mice, FSH exposure increased atherosclerosis. In GnRH agonist–treated mice, blocking of short FSH surge by anti-FSHβ antibody greatly alleviated endothelial inflammation and delayed atherogenesis. In GnRH antagonist–treated mice, FSH supplementation aggravated atherogenesis. Mechanistically, FSH, synergizing with TNF-α (tumor necrosis factor alpha), exacerbated endothelial inflammation by elevating VCAM-1 (vascular cell adhesion protein 1) expression through the cAMP/PKA (protein kinase A)/CREB (cAMP response element-binding protein)/c-Jun and PI3K (phosphatidylinositol 3 kinase)/AKT (protein kinase B)/GSK-3β (glycogen synthase kinase 3 beta)/GATA-6 (GATA-binding protein 6) pathways. In monocytes, FSH upregulated CD29 (cluster of differentiation 29) expression via the PI3K/AKT/GSK-3β/SP1 (specificity protein 1) pathway and promoted monocyte-endothelial adhesion both in vitro and in vivo. Importantly, FSHR knockdown by shRNA in endothelium of carotid arteries markedly reduced GnRH agonist–induced endothelial inflammation and atherosclerosis in mice.CONCLUSIONS:FSH is responsible for ADT-associated atherosclerosis by exaggerating endothelial inflammation and promoting monocyte-endothelial adhesion.

100 Deals associated with AS 900672-Enriched

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Infertility	Phase 2	US	Merck KGaA	01 Jan 2007
Infertility	Phase 2	US	Merck KGaA	01 Jan 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00553514 (CTgov)	Phase 2	Infertility	71	Recombinant human chorionic gonadotropin (r-hCG)+AS900672-Enriched 10 microgram (mcg)+Follitropin alfa 75 international unit (IU) (AS900672-Enriched 10 Mcg)	bzdcahyjsp(slivygxyvc) = zlppwhrofm nbytwbzbhv (imursrofuq, kqbnopjvng - qnagszyutp) View more	-	25 Jul 2013
				Recombinant human chorionic gonadotropin (r-hCG)+AS900672-Enriched 20 mcg+Follitropin alfa 75 international unit (IU) (AS900672-Enriched 20 Mcg)	bzdcahyjsp(slivygxyvc) = yproeyyxhq nbytwbzbhv (imursrofuq, gpluccnzpu - lhpfxmxitr) View more
NCT00505752 (CTgov)	Phase 2	Infertility	520	Recombinant human chorionic gonadotropin (r-hCG)+AS900672-Enriched 50 microgram (mcg)+Follitropin alfa 150 international unit (IU) (AS900672-Enriched 50 Mcg)	eplocqxdln(ekpehvgjdn) = tgntljigxa efnpiztdjm (dvkwuwxkqk, omvfughoqp - neoolxysbf) View more	-	24 Jul 2013
				Recombinant human chorionic gonadotropin (r-hCG)+Follitropin alfa 150 international unit (IU) (Follitropin Alfa 150 IU)	eplocqxdln(ekpehvgjdn) = vtedpdjojt efnpiztdjm (dvkwuwxkqk, lnzwqzmuvd - bkvyvgvibm) View more